Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401.

Anna Serwotka-Suszczak,Alicja Sochaj-Gregorczyk,Daniel Krowarsch,Jacek Otlewski,Jerzy Pieczykolan,Filip Jelen

doi:10.3390/ijms19113676

Abstract

It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [...].

Highlights

M. et al A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
It has been brought to our attention that the affiliation of Dr Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [1] was not mentioned in the previous published version
Add the following affiliation as the current address of Dr Jerzy Pieczykolan: Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; jerzy.pieczykolan@celonpharma.com. This correction does not cause any changes to results and conclusions in the original published paper

Summary

Introduction

M. et al A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Sochaj-Gregorczyk 1, Jerzy Pieczykolan 2,† , Daniel Krowarsch 3 , Filip Jelen 4 and Jacek Otlewski 1,* Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland; aniaserwotka@wp.pl (A.M.S.-S.); alicja.sochaj-gregorczyk@uj.edu.pl (A.M.S.-G.)

Results

Conclusion